FCF YoY
+37.58%
OCF YoY
+26.80%
Capex YoY
-8.09%
FCF Conversion Δ
+6.5 pp
Free cash flow bridge for Regeneron Pharmaceuticals (REGN) — TTM through Q1 2026 vs TTM through Q1 2025
Δ Free cash flow: $1.14B
FCF bridge breakdown for Regeneron Pharmaceuticals (REGN) — TTM through Q1 2026 vs TTM through Q1 2025
| Driver | Contribution | % of Δ |
|---|---|---|
| Prior Free Cash Flow | $3.02B | — |
| Operating Cash Flow | $1.06B | +93.3% |
| Capital Expenditure | $75.50M | +6.7% |
| Free Cash Flow | $4.16B | — |
- Prior Free Cash Flow$3.02B
- Operating Cash Flow$1.06B
- Capital Expenditure$75.50M
- Free Cash Flow$4.16B
Identity check: drivers reconcile to ΔNI within $0.00 ✓
Want to see how cash flow is built up?Cash Flow Waterfall
Frequently asked questions
Data & methodology
Regeneron Pharmaceuticals (REGN) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Cash Flow
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement